Komori
Other Disclosures4572Carna Biosciences,Inc.Pharmaceuticals

Notice of Patent Allowance in Japan for Manufacturing Intermediates for the BTK Inhibitors docirbrutinib (AS-1763), sofnobrutinib (AS-0871) and Others

In Japan, a patent grant decision was issued for compounds and manufacturing methods that can be used for manufacturing intermediates of BTK inhibitors such as docirbrutinib (AS-1763) and sofnobrutinib (AS-0871). The patent is now at the stage where it will be registered upon payment of the registration fee.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

docirbrutinib（AS-1763）sofnobrutinib（AS-0871）Fluoroisoquinoline compounds and methods for producing them
Applicable field (uses covered by this announcement)

Treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma, immune and inflammatory diseases, skin diseases, and kidney diseases

Registration number and expiry date

Application number: 特願2023-579969. A patent grant decision has been issued, and patent registration is planned after payment of the registration fee. Validity period: Not disclosed

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Japan Patent Office

Announced details
ItemDetails
Names of Products / Services Covereddocirbrutinib（AS-1763）, sofnobrutinib（AS-0871）, Fluoroisoquinoline compounds and methods for producing them
Applicable areaTreatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma, immune and inflammatory diseases, skin diseases, and kidney diseases
Registration number and expiry dateApplication number: 特願2023-579969. A patent grant decision has been issued, and patent registration is planned after payment of the registration fee. Validity period: Not disclosed
SourceJapan Patent Office
Items this document does not state (14)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Following examination by the Japan Patent Office, the inventions were deemed to merit the grant of patent rights. The company explained that this patent grant decision expands the scope of rights to include manufacturing intermediates for BTK inhibitors, further strengthening its patent portfolio.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Patent Allowance in Japan for Manufacturing Intermediates for the BTK Inhibitors docirbrutinib (AS-1763), sofnobrutinib (AS-0871) and Others | Carna Biosciences,Inc. (4572) timely disclosure | Komori